Cargando…

A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias

Low magnesium may increase the risk of atrial fibrillation. We conducted a double-blind pilot randomized trial to assess adherence to oral magnesium supplementation (400 mg of magnesium oxide daily) and a matching placebo, estimate the effect on circulating magnesium concentrations, and evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lutsey, Pamela L., Chen, Lin Y., Eaton, Anne, Jaeb, Melanie, Rudser, Kyle D., Neaton, James D., Alonso, Alvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073799/
https://www.ncbi.nlm.nih.gov/pubmed/29996476
http://dx.doi.org/10.3390/nu10070884
_version_ 1783344270786166784
author Lutsey, Pamela L.
Chen, Lin Y.
Eaton, Anne
Jaeb, Melanie
Rudser, Kyle D.
Neaton, James D.
Alonso, Alvaro
author_facet Lutsey, Pamela L.
Chen, Lin Y.
Eaton, Anne
Jaeb, Melanie
Rudser, Kyle D.
Neaton, James D.
Alonso, Alvaro
author_sort Lutsey, Pamela L.
collection PubMed
description Low magnesium may increase the risk of atrial fibrillation. We conducted a double-blind pilot randomized trial to assess adherence to oral magnesium supplementation (400 mg of magnesium oxide daily) and a matching placebo, estimate the effect on circulating magnesium concentrations, and evaluate the feasibility of using an ambulatory heart rhythm monitoring device (ZioPatch) for assessing premature atrial contractions. A total of 59 participants were randomized; 73% were women, and the mean age was 62 years. A total of 98% of the participants completed the follow-up. In the magnesium supplement group, 75% of pills were taken, and in the placebo group, 83% were taken. The change in magnesium concentrations was significantly greater for those given the magnesium supplements than for those given the placebo (0.07; 95% confidence interval: 0.03, 0.12 mEq/L; p = 0.002). The ZioPatch wear time was approximately 13 of the requested 14 days at baseline and follow-up. There was no difference by intervention assignment in the change in log premature atrial contractions burden, glucose, or blood pressure. Gastrointestinal changes were more common among the participants assigned magnesium (50%) than among those assigned the placebo (7%), but only one person discontinued participation. In sum, compliance with the oral magnesium supplementation was very good, and acceptance of the ZioPatch monitoring was excellent. These findings support the feasibility of a larger trial for atrial fibrillation (AF) prevention with oral magnesium supplementation.
format Online
Article
Text
id pubmed-6073799
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60737992018-08-13 A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias Lutsey, Pamela L. Chen, Lin Y. Eaton, Anne Jaeb, Melanie Rudser, Kyle D. Neaton, James D. Alonso, Alvaro Nutrients Article Low magnesium may increase the risk of atrial fibrillation. We conducted a double-blind pilot randomized trial to assess adherence to oral magnesium supplementation (400 mg of magnesium oxide daily) and a matching placebo, estimate the effect on circulating magnesium concentrations, and evaluate the feasibility of using an ambulatory heart rhythm monitoring device (ZioPatch) for assessing premature atrial contractions. A total of 59 participants were randomized; 73% were women, and the mean age was 62 years. A total of 98% of the participants completed the follow-up. In the magnesium supplement group, 75% of pills were taken, and in the placebo group, 83% were taken. The change in magnesium concentrations was significantly greater for those given the magnesium supplements than for those given the placebo (0.07; 95% confidence interval: 0.03, 0.12 mEq/L; p = 0.002). The ZioPatch wear time was approximately 13 of the requested 14 days at baseline and follow-up. There was no difference by intervention assignment in the change in log premature atrial contractions burden, glucose, or blood pressure. Gastrointestinal changes were more common among the participants assigned magnesium (50%) than among those assigned the placebo (7%), but only one person discontinued participation. In sum, compliance with the oral magnesium supplementation was very good, and acceptance of the ZioPatch monitoring was excellent. These findings support the feasibility of a larger trial for atrial fibrillation (AF) prevention with oral magnesium supplementation. MDPI 2018-07-10 /pmc/articles/PMC6073799/ /pubmed/29996476 http://dx.doi.org/10.3390/nu10070884 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lutsey, Pamela L.
Chen, Lin Y.
Eaton, Anne
Jaeb, Melanie
Rudser, Kyle D.
Neaton, James D.
Alonso, Alvaro
A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias
title A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias
title_full A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias
title_fullStr A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias
title_full_unstemmed A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias
title_short A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias
title_sort pilot randomized trial of oral magnesium supplementation on supraventricular arrhythmias
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073799/
https://www.ncbi.nlm.nih.gov/pubmed/29996476
http://dx.doi.org/10.3390/nu10070884
work_keys_str_mv AT lutseypamelal apilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT chenliny apilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT eatonanne apilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT jaebmelanie apilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT rudserkyled apilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT neatonjamesd apilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT alonsoalvaro apilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT lutseypamelal pilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT chenliny pilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT eatonanne pilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT jaebmelanie pilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT rudserkyled pilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT neatonjamesd pilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias
AT alonsoalvaro pilotrandomizedtrialoforalmagnesiumsupplementationonsupraventriculararrhythmias